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ABSTRACT
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder 
classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. 
HCLv is characterized by unfavorable prognosis, low complete remission rates and 
limited disease control following classical hairy cell leukemia-based regimens. In 
this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-
mutated HCLv, who were effectively treated with four cycles of bendamustine plus 
rituximab. The regimen was completed in all the patients with acceptable toxicity. All 
patients achieved a complete clinical response with no evidence of residual disease 
at bone marrow biopsy and flow-cytometry examination. After a median follow-up of 
19 months, the 3 subjects are still in complete remission. In this work, bendamustine 
plus rituximab proved to be an effective and feasible first-line treatment strategy for 
elderly patients with TP53 un-mutated HCLv.
MAIN TEXT
Hairy cell leukemia (HCL) variant (HCLv) is a 
rare chronic lymphoproliferative disorder, classified as a 
provisional entity among the unclassifiable splenic B-cell 
lymphoma category in the 2008 and updated 2016 World 
Heath Organization Classification of hematopoietic and 
lymphoid tissue tumors. HCLv is characterized by peculiar 
immunophenotypic, molecular and clinical features that 
significantly differ from those of classical HCL  [1]. HCLv 
represents 10% of all HCL, with an estimated incidence of 
0.3 cases per 1.000.000 people/year.
HCLv usually affects elderly males and is 
characterized by splenomegaly, lymphocytosis 
and cytopenia, without monocytopenia. Although 
lymphocytosis is a typical feature of HCLv and helps in 
the differential diagnosis with classical HCL, significant 
variations in lymphocyte levels have been reported [2] and 
almost 10% of HCLv patients may present with a normal 
white blood cell count [3]. Leukemic-HCLv cells express 
mature B cell markers (CD19, CD20 and CD22), CD11c 
and CD103 but, unlike classical HCL, they are often 
negative for CD25 and CD123. Somatic hypermutations 
in the immunoglobulin heavy chain gene are detected in 
almost 70% of patients with a preferential usage of the 
IGHV4-34 family [2, 4]. Data on recurrently mutated 
genes in HCLv are scanty; the BRAF V600E mutation 
is absent in HCLv [5], as compared with classical HCL, 
while MAP2K1 [6] and TP53 [7] mutations have been 
reported in 48% and 30% of cases, respectively. The 
prognosis in patients with HCLv is worse than that 
in HCL. The estimated 5-year overall survival rates 
for patients with HCLv and HCL are 57% and 80%, 
respectively [7, 8]. In particular, patients with advanced 
age, anemia (Hb < 100 g/L) and TP53 mutations may face 
a poor survival outcome [7].
                                                          Case Report
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The treatment of HCLv is challenging, since 
effective first line agents for classical HCL (i.e. the 
purine analogs, 2′chlorodeoxyadenosine [2-CDA] or 
2′deoxycoformycin [DCF]) are of limited utility in 
HCLv, being characterized by rare complete responses 
(CR), partial responses in only half of the cases and a 
median duration of responses (DOR) of 15 months [3]. 
In literature, several single case reports of HCLv have 
been reported following treated with weekly single agent 
rituximab with complete recovery of cytopenias within 3 
months after treatment [9–11]. These preliminary results 
induced physicians to combine purine analogs with anti-
CD20 antibody. Ravandi et al. documented a high activity 
of 2-CDA administrated at day 1 to 5 followed by 8 
weekly doses of Rituximab, with 3 out of 5 HCLv patients 
achieving a CR with a DOR of 12 months [12]. Kreitman 
et al. used a different schedule of 2-CDA plus Rituximab, 
with the monoclonal antibody infused on day 1. Nine of 
10 patients achieved a CR and 8 of them maintained the 
response with a median follow-up of 27 months [13]. 
These data pointed out that the combination of 2-CDA 
plus rituximab was significantly superior to 2-CDA alone, 
as employed in previous studies, but these results are 
derived only from 10 [13] and 5 [12] patients, respectively.
As a consequence, new treatment strategies are 
needed to improve responses, to prolong the survival of 
patients and to manage relapsed diseases. 
In this retrospective study we investigated the 
activity and the therapeutic effect of the combination of 
bendamustine plus rituximab (BR) in 3 treatment naïve 
patients with HCLv, followed at the Hematology and 
Clinical Immunology unit of Padua University hospital.
Patients were diagnosed to be affected by HCLv 
following flow cytometry analysis on peripheral blood, 
according to Shao H. et al. [2]. Criteria for starting 
treatment were neutrophil count < 1,000/µL, hemoglobin 
(Hb) < 10 g/L, platelets (PLT) < 100,000/µL, lymphocytes 
> 5,000/µL, symptomatic splenomegaly and enlarged 
nodes > 1.5 cm. All patients performed bone marrow 
biopsy and marrow flow cytometry before treatment and 
within six weeks after the end of treatment. The estimated 
glomerular filtration rate (eGFR) was calculated using 
the Cockcroft-Gault formula. BRAFV600E and TP53 
mutations were analyzed on purified HCL cells from 
peripheral blood and performed as reported by Tiacci 
[5] and Hockely [7]. Patients received bendamustine at 
70 mg/m2 on day 1 and 2 and rituximab 375 mg/m2 on 
day 1 every 28 days for 4 cycles. Pneumocystis and anti-
viral prophylaxis were performed with thrimetophrim-
sulfametoxazol 800–160 mg ½ compress and acyclovir 
400 mg 1 compress every day till 6 months after the last 
cycle. Response evaluation was assessed according to 
2015 ESMO guidelines [14].
Patients’ features are summarized in Table 1. Subjects 
were elderly, with a median age at the time of treatment 
of 83 years. The median number of comorbidities and 
CIRS score were 4 and 7, respectively. They did not have 
history of recurrent infections nor autoimmune diseases. 
The median white blood cells count was 17,800 cells/
µL and the median absolute neutrophil count was 2,853 
cells/µL. The median Hb and PLT levels were 107 g/L 
and 97,000/µL, respectively. All patients had enlarged 
spleens with the lower margin reaching the umbilical 
transverse line but no lymphadenopathies were detected. 
Peripheral blood films (Supplementary Figure 1) from the 
three patients revealed abnormal, medium to large size 
lymphocytes with abundant and irregular cytoplasm and 
fine circumferential projections, round eccentric nuclei 
and a prominent nucleolus. In patient #2 we also observed 
rare bi-nucleated cells. By flow-cytometry we identified 
light-chain restricted B cells that were brightly positive for 
CD20, CD22 and CD11c, positive for CD19 and CD103 
but negative for CD5, CD23, CD25 and CD123. The 
BRAF V600E mutation was absent in all three cases. TP53 
mutations were tested in subject #1 and #3 and were not 
present. Bone marrow was easily aspirated for all patients 
and trephine biopsy (Figure 1E) showed normal maturing 
trilineage hematopoiesis with a subtle intra-sinusoidal 
and/or interstitial lymphocytic infiltrate, composed of 
medium-sized cells with pale cytoplasm. Nodular lymphoid 
aggregates, plasma cell differentiation and/or diffuse 
stromal invasion with peri-adipocytic lymphocytic rosettes 
were not documented. Reticulin stain showed only focal 
to mild bone marrow fibrosis. By immunohistochemistry, 
neoplastic cells displayed strong positivity for pan-B cell 
markers (CD20, CD22 Figure 1E–1F) and Bcl2 (Figure 1G), 
with consistent negativity for CD3, CD5, CD23, CD25, 
Annexin A1, Cyclin D1 and the BRAF V600E-specific 
antibody (Supplementary Figure 2).
Based on clinical, flow cytometry and histological 
features of the lymphoid infiltrate a final diagnosis of 
HCLv was obtained.
As shown in Table 1, patient #1 required treatment 
for lymphocytosis, symptomatic splenomegaly and low 
PLT count, #2 for anemia and #3 for lymphocytosis, 
anemia and thrombocytopenia. 
The treatment was well tolerated and all patients 
completed the planned 4 cycles without time delay.  A 
decrease in lymphocyte count and an improvement of 
cytopenia were observed after starting treatment, as 
reported in Figure 1A–1D. Fatigue and splenomegaly-
associated symptoms resolved completely as long with 
the reduction of spleen size (median longitudinal spleen 
diameter at CT scan before and after treatment: 18.3 cm 
vs 13.3 cm; p = 0.0082). Patient #3 developed a G3 
neutropenia during the third cycle and patient #2 had a 
transient G2 increase of hepatic cytolytic enzymes during 
the second cycle.
The overall response rate (ORR) was 100%. All 
patients achieved a CR, as confirmed by the normalization 
of blood cell count and by the absence of leukemic cells 
at post-therapy immunohistochemical (CD20 and CD22) 
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and flow-cytometry marrow examination (representative 
pre- and post-treatment histological findings for patient 
#2 are reported in Figure 1E–1L). After a median follow-
up of 19 months from the beginning of treatment (range: 
18–20 months), all subjects were on CR, with no evidence 
of splenomegaly or circulating clonal B cells.
Bendamustine has features of both alkylating and 
purine analog drugs. It lacks cross resistance with other 
alkylating agents and its multiple mechanisms of action 
include the activation of DNA damage responses and the 
base excision repair pathway, the inhibition of mitotic 
checkpoints, the activation of p53 and the induction of 
mitotic catastrophe [15].
In the last years, different groups demonstrated 
that the addition of rituximab to bendamustine is able to 
induce deep and durable response in several indolent non-
Figure 1: Complete blood count values and bone marrow biopsy. In the top-half of the figure are reported data on (A) total white blood 
cell count, (B) hemoglobin, (C) platelets and absolute neutrophil count (D) from the 3 patients with HCLv before starting treatment (pre), at the 
first (I), second (II), third (III) and four (IV) cycles of bendamustine plus rituximab, after one and six months from the end of therapy. In the low-
half of the figure there are representative histologic features of pre- and post-treatment HCLv (E–L). Pre-treatment bone marrow biopsy showed 
an interstitial infiltrate of small to medium size lymphocytes with abundant, pale cytoplasm (E). Immunohistochemical analysis (CD20 and CD22 
antigen) confirmed the presence of interstitial and intra-sinusoidal neoplastic B-cells (F–G). Post-treatment biopsy showed normal cellularity with 
trilinear hematopoiesis (H). Negative CD20 and CD22 immunostaining were consistent with complete histologic responses (I–L).
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Hodgkin lymphoma and in mantle cell lymphoma [16–18]. 
In many of these settings, such an approach has proven 
safe and efficacious in heavily pretreated patients and in 
older populations without major toxicities. 
However, little in known on the activity of BR in 
classical HCL and its effects on HCLv have not been 
characterized. Burotto et al. demonstrated that BR 
was able to induce 100% of ORR with 58% CR and 
sustained disease remission in 12 relapsed or refractory 
classical HCL [19]. The median age of this group 
was 62 years, ranging from 55 to 70 years. The most 
common grade 3–4 adverse events were lymphopenia, 
thrombocytopenia, neutropenia, rituximab infusion 
reaction and transaminase elevation. Recently, Bohn 
JP et al. described a case of an 82-year-old male with 
HCLv treated with BR as first-line therapy, which was 
stopped after the third cycle for sever cutaneous toxicity. 
Two years later, the patient relapsed and received 2-CDA 
and ofatumumab without any clinical improvement. The 
subsequent administration of ibrutinib was associated 
with a good disease control even after 16 months of 
follow-up [20].
In conclusion, alternative treatment approaches are 
needed for patients with HCLv, given the more aggressive 
clinical course as compared to classical HCL and the lack 
of effective therapeutic regimens. We reported 3 elderly 
treatment-naive HCLv patients with impaired renal 
function, who were successfully managed with BR. All 
the patients completed the planned 4 courses of treatment, 
achieved a complete response and experienced acceptable 
toxicities profiles (comparable with those reported in 
other works). We, herein, provided evidence that the 
combination of bendamustine plus rituximab represents 
an effective and feasible first-line treatment strategy in 
elderly patients with TP53 un-mutated HCLv.
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